Drawing for LOVE TOKEN

USPTO serial 97308316

LOVE TOKEN

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
ALESKOW, DAVID HOWARD
Law office
TMEG LAW OFFICE 105 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with LOVE TOKEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kenneth I. Kohn

KENNETH I. KOHN KOHN AND ASSOCIATES PLLC30500 NORTHWESTERN HIGHWAYSUITE 410FARMINGTON HILLS, MI 48334

Goods and services

ClassDescriptionStatusFirst use
036virtual currency monetary token used by a company whose goods and services include operating clinical trials; operating virtual clinical trials; operating decentralized clinical trials; operating decentralized virtual clinical trials; the development of pharmaceuticals; the assessment of pharmaceuticals; providing information about pharmaceuticals; the sale of pharmaceuticals; the testing of pharmaceuticals; the treatment of infections; the treatment of disease; the treatment of illness; creating, testing, selling, and providing information about pharmaceuticals for the treatment of viral infections, neoplastic, metabolic, autoimmune, or inflammatory disorders; providing healthcare services; providing health management programs; providing a health database; health management featuring inputting and collection of data and information all for treatment and diagnostic purposes; providing a full line of pharmaceutical preparations; educational services, namely, providing electronic publications in the nature of articles and newsletters in the field of pharmaceuticals and healthcare to healthcare professionals and patients; healthcare services, namely, providing information in the field of health via the internet; the use of artificial intelligence to analyze photographs for the purpose of making health recommendations or diagnosing or treating any disease; providing health diagnostic services; providing health care; providing health planning tools; providing dietary recommendations; generating personalized health supplements and recommendations; evaluating third-party health supplements and programs; selling health and wellness supplements and programs; hosting a marketplace for health and wellness supplements and programs; providing exercise recommendations; providing testing material for biotechnology firms; providing virtual and in-person health assessments; running in-person and virtual medical surveys; providing treatment programs for addiction and recovery; and running virtual and in-person medical studiesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Jun 5, 2023MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 5, 2023MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 5, 2023ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Nov 20, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 20, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 20, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 3, 2022DOCKASSIGNED TO EXAMINER—
Mar 16, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—

Frequently asked questions

Related guidance